Company Overview
Sensei Biotherapeutics, Inc. operates as a clinical-stage biotechnology company dedicated to the discovery and development of therapeutics specifically designed for cancer patients. The enterprise focuses on its Tumor Microenvironment Activated Biologics platform, a technology aimed at generating highly selective therapeutics that disable immunosuppressive mechanisms within the tumor environment. This company functions within the Healthcare sector, specifically the Biotechnology industry, which typically involves high levels of research and development spending with products that require rigorous clinical validation before market approval. The firm currently maintains a market capitalization of $34.92M and employs 14 individuals to support its operational and scientific objectives. These financial metrics indicate that the company is a small-cap entity with limited current revenue generation, reflecting the typical trajectory of clinical-stage biotechnology firms that are still navigating the costly and time-intensive phases of drug development prior to commercialization.
Financial Health
The company reports a Net Income of $-24,138,000 and an EBITDA of $-23,518,000 over the trailing twelve-month period, while Revenue figures are listed as N/A, indicating that the business has not yet generated significant commercial sales. The substantial gap between the reported net income and EBITDA, alongside the absence of revenue, reveals a cost structure dominated by research, development, and administrative expenses typical of pre-revenue life sciences companies. Free Cash Flow stands at $-13,303,000, a figure that signifies the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity from core business activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a status that is consistent with the company's lack of revenue and indicates that no gross profit or operating leverage has been established yet. On the balance sheet, the company holds $25.04M in cash against $2.02M in debt, resulting in a Debt to Equity ratio of 8.78 which suggests a capital structure heavily reliant on equity financing rather than borrowed funds. The Current Ratio is 5.81, a metric that indicates strong short-term liquidity and suggests the company possesses ample current assets to cover its short-term liabilities without immediate risk of insolvency. Return on Equity is -70.2% and Return on Assets is -37.0%, metrics that reveal the company is currently generating negative returns on its capital base as it invests heavily in future potential rather than producing current profits.
Valuation Assessment
The P/E Ratio (TTM) is N/A due to the lack of net income, while the Forward P/E is listed as -24.71, implying that the market is pricing in negative earnings expectations based on projected future performance rather than historical profitability. The Price to Book ratio is 1.52, which indicates that the stock is trading at a premium of 52% over its book value, a valuation characteristic often seen in biotechnology stocks where investors assign value to intangible assets like intellectual property and pipeline potential. The Price to Sales ratio is N/A and the EV/EBITDA is -0.51, suggesting that traditional valuation multiples are not applicable or are negative, which points to a reliance on alternative valuation methods such as discounted cash flow models or comparable company analysis for this stage of development. The 52-Week High is $36.76 and the 52-Week Low is $5.00, providing a range within which the stock has traded; without a specific current price provided in the facts, the valuation context relies on these historical bounds to demonstrate the stock's recent volatility and trading range. The Beta is -0.08, a highly unusual negative value that implies the stock's price movements have historically moved inversely to the broader market or displayed negligible correlation with market indices, suggesting a distinct volatility profile that differs from the majority of equity instruments.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated from recent sales data. Because the company has not yet generated commercial revenue, there is no earnings growth trajectory to compare against revenue, and the negative financial results are intrinsic to the clinical-stage development model rather than a sign of operational inefficiency. As a non-dividend payer, the company does not distribute dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that any theoretical earnings would be reinvested into research and development rather than distributed to shareholders. The overall growth and income profile is characterized by a lack of current financial returns and cash generation, which is standard for clinical-stage biotechnology companies that prioritize capital allocation toward advancing their therapeutic candidates through clinical trials.